Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | THRA | P10827 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3146277 | 1.00 | NPC1 (0.54) | NPC1MAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL3151243 | 0.90 | MAPT (0.52) | NPC1MAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL3146280 | 0.88 | ALDH1A1 (0.53) | MAPTKMT2AALDH1A1MEN1HPGD | |
| SCHEMBL14096284 | 0.85 | MAPT (0.54) | NPC1MAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL3150338 | 0.85 | MAPT (0.57) | NPC1MAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3150260 | 0.85 | MAPT (0.57) | NPC1MAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3146275 | 0.84 | S1PR1 (0.43) | MAPTKMT2AALDH1A1MEN1HPGD | |
| SCHEMBL3146118 | 0.84 | MAPT (0.58) | NPC1MAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3136511 | 0.82 | THRB (0.52) | NPC1MAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL2864670 | 0.81 | NPC1 (0.49) | NPC1MAPTKMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1747196-B1 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS INC (US) | 2010-02-10 | — | — | EP | claimed |
| US-7365068-B2 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-04-29 | — | — | US | claimed |
| US-7767706-B2 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767706-B2 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| EP-1747196-B1 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS INC (US) | 2010-02-10 | — | — | EP | disclosed |
| US-20100029652-A1 | Combination Therapy For Treating Hepatitis C Infections | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| CN-101563076-A | Combination therapy for treating hepatitis C infections | ACHILLION PHARMACEUTICALS INC (US) | 2009-10-21 | — | — | CN | disclosed |
| EP-2091524-A2 | COMBINATION THERAPY FOR TREATING HEPATITIS C INFECTIONS | Achillion Pharmaceuticals, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20090023730-A1 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023730-A1 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS (US) | 2009-01-22 | — | — | US | disclosed |
| WO-2008076443-A2 | COMBINATION THERAPY FOR TREATING HEPATITIS C INFECTIONS | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-7365068-B2 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365068-B2 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365068-B2 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-20060025416-A1 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-02-02 | — | — | US | disclosed |
| US-20060025416-A1 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029652-A1 | Combination Therapy For Treating Hepatitis C Infections | HAVCR2, SLC10A1, CYP7A1 | NPC1 25/4885MAPT 3772/4885KMT2A 4014/4885 |
| US-20060025416-A1 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | PIGS, NAT1, AADAC | NPC1 179/4885MAPT 3157/4885KMT2A 1501/4885 |
| US-20090023730-A1 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | PIGS, NAT1, AADAC | NPC1 179/4885MAPT 3157/4885KMT2A 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.